Amylin Halts Development Of Symlin With Approved Appetite Suppressants
This article was originally published in The Pink Sheet Daily
Executive Summary
The 2009 filing timeline for once-weekly exenatide could be hastened if FDA does not require bioequivalence data, firm says.
You may also be interested in...
Amylin Obesity Combo Scores Big Weight Loss In Phase IIa Trial
Subjects taking pramlintide/metreleptin lost a significant 12.7 percent of body weight compared with 8.4 percent for subjects on pramlintide alone.
Amylin/Lilly’s Once-Weekly Exenatide Wins Head-To-Head Over Byetta
Firms expect to file NDA by end of first half 2009.
Byetta Is “Approvable” As Stand-Alone Therapy
Lilly/Amylin'sByetta type 2 diabetes agent is "approvable" at FDA as a stand-alone therapy in conjunction with the April 29 approval of exenatide as an adjunct to other oral treatments, the firms said